Anavex Life Sciences Corp (AVXL)

[OFP]

OFP. You have overlooked the fact that Biogen has had 2-73 in their labs for 7 or 8 months

10 months since the agreement was announced. Far more time than needed to do this testing and much more.

may show remyelination capabilities which would have very significant impact on their core M/S business.

Actually, there was never any reason to expect an impact even if the testing were positive. There are many compounds available that have been shown to promote OPC differentiation. To me, this always seemed to be primarily a PR opportunity to say they had some association with BP.

their Phase three trial of Aducanumab is said to be costing them in the area of $1B. Might they be looking at 2-73's P2 data and comparing it to Aducanumab's

Last thing they want is a new costly trial with low prospects. They would want to see data that far exceeds what 2-73 has to offer...i.e. positive results in a reasonably crafted efficacy trial (obviously including placebo control).